Biotech Express Bureau
Amid the race to develop a potential Covid-19 vaccine in India, the Indian government today launched an COVID Vaccine and Clinical Registry portal for information and updates on the various Covid-19 vaccine being produced in the country, announced Union Health Minister Harsh Vardhan but no single vaccine depicts the contribution of any Indian Govt lab in the development of vaccine and no development has come from PSA office which has received Rs. 100 crore from PM CARES fund.
The online portals hosted by Indian Council of Medical Research (ICMR) site, will be a repository for all information related to vaccine development in India (https://vaccine.icmr.org.in/). India is currently on different phases of clinical trials of three COVID-19 vaccines.
The phase-III or the last stage of clinical trial of the COVID-19 vaccine ‘Covishield’, being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital in Pune, Maharashtra on Monday, a senior official said. The Covishield vaccine will be administered as a dose to 150 to 200 volunteers, official had said.
India’s indigenous vaccine developers Bharat Biotech International Ltd. are at the second-phase human trial stage and Zydus Cadila is in the process to receive approvals for conducting third-phase clinical trials.
Currently, the Uttar Pradesh government announced that phase-3 trial of the coronavirus vaccine ‘COVAXIN’ will start in Lucknow and Gorakhpur from October.
SII has also started manufacturing COVID-19 vaccine candidate developed by Codagenix Inc, the US biotech said in a statement. Meanwhile, Serum’s CEO Adar Poonawalla calling the distribution of a Covid-19 vaccine to 1.3 billion population of India, “concerning challenge” said that the government may need ₹80,000 crore over the next one year for distribution of covid-19 vaccine to every person in India.
Moreover, India’s vaccine manufacturer recently announced a licensing agreement with Washington University School of Medicine in the US for a single dose intranasal vaccine for COVID-19 based on a novel chimpanzee adenovirus. The pact gives the Hyderabad-based vaccine developer the rights to distribute the vaccine in all markets except the US, Japan and Europe, reported Mint. Under the pact, phase I trials will take place in the university’s Vaccine and Treatment Evaluation Unit, while Bharat Biotech will undertake further stages of clinical trials in India and large-scale manufacturing of the vaccine at its facility in Genome Valley, Hyderabad.
Earlier reports suggest that in the first stage, the ICMR vaccine portal will reflect the information on COVID-19 vaccine development in India. However, with time, the web portal will be strengthened with data available for all the vaccines used to prevent various diseases.